(Total Views: 717)
Posted On: 05/05/2020 4:11:51 AM
Post# of 148934
Researchgate Article mentions Leronlimab against Covid-19!
Day by day....final is near!
COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
7.4. Convalescent plasma and monoclonal antibodies
Convalescent plasma and monoclonal antibodies are suggested therapies for the treatment of COVID-19 patients. Convalescent plasma or immunoglobulins are used as a last resort to improve the survival rate
of patients with SARS, whose condition continued to deteriorate after pulsed methylprednisolone therapy71. In addition, some studies found a shorter
hospital stay and lower mortality in patients treated with convalescent plasma72 .
Further probability includes Leronlimab, a humanized monoclonal
antibody (CCR5 antagonist), and a nucleoside RNA polymerase inhibitor galidesivir, both of which have shown survival benefits in many deadly virus
infections and are considered potential useful candidates for treatment73, 74
.
https://www.researchgate.net/profile/Shah_Fai...avirus.pdf
Day by day....final is near!
COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
7.4. Convalescent plasma and monoclonal antibodies
Convalescent plasma and monoclonal antibodies are suggested therapies for the treatment of COVID-19 patients. Convalescent plasma or immunoglobulins are used as a last resort to improve the survival rate
of patients with SARS, whose condition continued to deteriorate after pulsed methylprednisolone therapy71. In addition, some studies found a shorter
hospital stay and lower mortality in patients treated with convalescent plasma72 .
Further probability includes Leronlimab, a humanized monoclonal
antibody (CCR5 antagonist), and a nucleoside RNA polymerase inhibitor galidesivir, both of which have shown survival benefits in many deadly virus
infections and are considered potential useful candidates for treatment73, 74
.
https://www.researchgate.net/profile/Shah_Fai...avirus.pdf
(2)
(0)
Scroll down for more posts ▼